Patients are being enrolled in Closure Medical’s trial of a new synthetic vascular sealant product.

The trial has been approved by the FDA.

The sealant, which is the first product developed by Closure for internal use. Is designed to seal veins, arteries and artificial grafts that can leak after suturing, according to the company.

Ten patients will be tested, undergoing an arteriovenous shunt to receive the artificial graft.

“Being able to treat indications inside the human body requires a much more advanced formulation, the development of which demonstrates the breadth of our core competence,” said Daniel Pelak, chief executive officer of Closure. He said the test is a “milestone” for the firm.